Grant for waiting instead of intervention in precursor of breast cancer


The Rising Tide Foundation For Clinical Research (RTFCCR) is awarding €800,000 to Jelle Wesseling's LORD study. This study, ongoing since 2017, investigates whether non-treatment of a common precursor abnormality of breast cancer, known as Ductal Carcinoma In Situ (DCIS), is safe.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.